Ketazocine

Ketazocine

Systematic (IUPAC) name
(2S,6R,11R)-3-(cyclopropylmethyl)-8-hydroxy-6,11-dimethyl-3,4,5,6-tetrahydro-2,6-methano-3-benzazocin-1(2H)-one
Clinical data
Routes of administration	Oral
Legal status
Legal status	?
Identifiers
CAS Number	36292-69-0
ATC code	none
PubChem	CID 3054741
ChemSpider	2316328
UNII	6IO4IG518S
KEGG	D04649
Chemical data
Formula	C18H23NO2
Molar mass	285.38 g/mol
SMILES O=C2c1c(cc(O)cc1)[C@]3([C@H]([C@@H]2N(CC3)CC4CC4)C)C
InChI InChI=1S/C18H23NO2/c1-11-16-17(21)14-6-5-13(20)9-15(14)18(11,2)7-8-19(16)10-12-3-4-12/h5-6,9,11-12,16,20H,3-4,7-8,10H2,1-2H3/t11-,16-,18+/m0/s1 Key:HQBZLVPZOGIAIQ-SDDDUWNISA-N
(verify)

Ketazocine (INN), also known as ketocyclazocine, is a benzomorphan derivative used in opioid receptor research. Ketocyclazocine is an exogenous opioid that binds to the κ opioid receptor.^[1]

Activation of this receptor is known to cause sleepiness, a decrease in pain sensation and (potentially) dysphoria, paranoia, and hallucinations. It also causes an increase in urine production because it inhibits the release of vasopressin. (Vasopressin is an endogenous substance that assists in regulating fluid and electrolyte balance in the body and decreases the amount of water released into the urine.)

Unlike other opioids, substances that only bind to the κ receptor theoretically do not depress the respiratory system.

See also

• Benzomorphan
• Ethylketazocine

References

1. Leander JD (Sep 1982). "Effects of ketazocine, ethylketazocine and phenazocine on schedule-controlled behavior: antagonism by naloxone". Neuropharmacology 21 (9): 923–8. doi:10.1016/0028-3908(82)90085-5. PMID 6128693.